Rem3dy Health Raises €16 Million at £84 Million Valuation to Scale 3D‑Printed Personalised Nutrition Into the US, MENA, and India
Birmingham‑based health technology company Rem3dy Health has completed a €16 million (£14 million) funding round, valuing the company at £84 million. The raise was led by a group of global strategic investors including Japanese beverage group Suntory, Spanish brewer Estrella Galicia, Indian healthcare provider Apollo Hospitals, and French pharmaceutical company UPSA. Birmingham‑based Future Planet Capital Regional also participated, reinforcing the company's regional roots. The announcement was made on June 9, 2026.
The capital will fund international market entry in the United States, the MENA region, and India, continued investment in automation and advanced manufacturing, further development of the company's AI‑driven personalisation platform, and a new expansion into personalised health products for pets.
What Rem3dy Health Builds
Founded in 2019 by Melissa Snover, Rem3dy Health is the parent company of Nourished, a personalised nutrition brand that uses patented 3D printing technology to produce tailored vitamin and supplement gummies. The company's core product is a stacked gummy in which each layer delivers a different active ingredient, formulated according to an individual customer's health profile, goals, and dietary requirements. That personalisation is driven by an AI‑based assessment that selects and combines the right stack of nutrients for each person from a library of active ingredients.
The manufacturing process, which combines data science, 3D printing, and automation, allows Rem3dy to produce approximately 500,000 personalised gummies per day. The company holds 29 patents covering its technology and formulations. Its products are available through Boots, Holland and Barrett, and Ocado in the UK, as well as direct‑to‑consumer through the Nourished platform. Production yield has reached 97 percent, a figure that reflects the maturity of the manufacturing process after several years of iteration.
The name Rem3dy is itself a hint at the company's ambition. The "3" signals three things: health, technology, and manufacturing, the three pillars around which Snover has built the business.
A Year of Transformation Behind the Raise
The funding follows a strong 2025 for the company. Revenue grew 61 percent year‑on‑year to £10.2 million in the year ended December 2025, a performance that demonstrates the business is moving beyond early‑adopter traction into broader commercial scale. The growth came alongside meaningful operational improvements, with production yield climbing to the 97 percent figure cited above.
This raise is not the company's first external capital, but it is its largest and its most strategically constructed. A £1.4 million round in late 2025, led by Borski Fund and Future Planet Capital Regional, was followed by a £9 million round in October 2025 to expand manufacturing capacity. The €16 million announced this week is the company's first round anchored primarily by global strategic investors rather than venture and impact funds. That shift matters. Strategic investors like Suntory, Apollo Hospitals, Estrella Galicia, and UPSA are not writing cheques purely for financial returns. Each brings distribution relationships, market access, or sector expertise that could meaningfully accelerate Rem3dy's entry into the markets it is targeting.
Estrella Galicia's participation is described by the company as signalling an expansion beyond traditional beverage categories. Apollo Hospitals, one of the largest integrated healthcare networks in Asia, brings direct clinical distribution and consumer health expertise across India and the broader region. Suntory brings deep consumer relationships in Japan and global wellness market knowledge. UPSA, with its pharmaceutical background, adds regulatory credibility.
Why These Three Markets, and Why Now
The United States is the most obvious target for a personalised nutrition brand with the technology and manufacturing capability Rem3dy has built. The US dietary supplement market is the largest in the world, and the shift toward personalised and functional nutrition has accelerated sharply. Rem3dy's product addresses precisely the segment of that market that is growing fastest, specifically consumers who want efficacy and personalisation rather than commodity multivitamins.
India and the MENA region represent a different opportunity profile. Both markets have large and growing middle classes with rising health awareness and high smartphone penetration, conditions that suit a direct‑to‑consumer health platform. Apollo Hospitals' involvement as a strategic investor is particularly relevant for the India push, given the network's scale across diagnostics, clinical care, and consumer health retail.
The pet health expansion is a calculated adjacency. The global pet care market has grown substantially, and the premium segment, including personalised nutrition for pets, mirrors the consumer trends that drove the human personalised nutrition category. The same 3D printing and AI personalisation infrastructure that Rem3dy has built for humans can be adapted for pets with relatively limited additional development, making it a logical extension of the existing platform rather than a new business.
Rupert Lyle, Investment Director at Future Planet Capital Regional, described the company as having a truly disruptive brand and technology capable of transforming the global wellness industry, and noted the regional significance of the raise for Birmingham's innovation ecosystem.
Against what Snover herself described as one of the toughest fundraising environments in recent years, the £84 million valuation and the calibre of the strategic investor base represent a meaningful endorsement of the business. The combination of patented manufacturing technology, an AI‑driven personalisation layer, a growing retail and direct‑to‑consumer footprint, and now global strategic backing gives Rem3dy Health a more credible international expansion platform than most consumer health startups can assemble at this stage.
